Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-β induced epithelial to mesenchymal transition
Tóm tắt
TGF-β acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis. However, later in tumor development TGF-β can become tumor promoting through mechanisms including the induction of epithelial-to-mesenchymal transition (EMT), a process that is thought to contribute to tumor progression, invasion and metastasis. To identify EMT-related breast cancer therapeutic targets and biomarkers, we have used two proteomic approaches to find proteins that change in abundance upon the induction of EMT by TGF-β in two mouse mammary epithelial cell lines, NMuMG and BRI-JM01. Preliminary experiments based on two-dimensional electrophoresis of a hydrophobic cell fraction identified only 5 differentially expressed proteins from BRI-JM01 cells. Since 3 of these proteins were glycoproteins, we next used the lectin, wheat germ agglutinin (WGA), to enrich for glycoproteins, followed by relative quantification of tryptic peptides using a label-free LC-MS based method. Using these approaches, we identified several proteins that are modulated during the EMT process, including cell adhesion molecules (several members of the Integrin family, Fibronectin, Activated leukocyte cell adhesion molecule, and Neural cell adhesion molecule 1) and regulators of cellular signaling (Tumor-associated calcium signal transducer 2, Basigin). Interestingly, despite the fact that TGF-β induces similar EMT phenotypes in NMuMG and BRI-JM01 cells, the proteomic results for the two cell lines showed only minimal overlap. These differences likely result in part from the conservative cut-off values used to define differentially-expressed proteins in these experiments. Alternatively, it is possible that the two cell lines may use different mechanisms to achieve an EMT transition.
Tài liệu tham khảo
Jakowlew SB: Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006,25(3):435–457.
Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007,39(3):305–318.
Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005,24(50):7443–7454.
Kang Y, Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004,118(3):277–279.
Thiery JP, Morgan M: Breast cancer progression with a Twist. Nat Med 2004,10(8):777–778.
Trainor PA, Melton KR, Manzanares M: Origins and plasticity of neural crest cells and their roles in jaw and craniofacial evolution. Int J Dev Biol 2003,47(7–8):541–553.
Lenferink AE, Magoon J, Cantin C, O'Connor-McCourt MD: Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition. Breast Cancer Res 2004,6(5):R514–530.
Miettinen PJ, Ebner R, Lopez AR, Derynck R: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994,127(6 Pt 2):2021–2036.
Demir AY, Demol H, Puype M, de Goeij AF, Dunselman GA, Herrler A, Evers JL, Vandekerckhove J, Groothuis PG: Proteome analysis of human mesothelial cells during epithelial to mesenchymal transitions induced by shed menstrual effluent. Proteomics 2004,4(9):2608–2623.
Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenberg DA, Reddy RC, Akulapalli S, Thannickal VJ, et al.: Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 2006,5(5):1143–1154.
Moreira JM, Gromov P, Celis JE: Expression of the tumor suppressor protein 14–3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004,3(4):410–419.
Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K: Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005,11(22):8006–8014.
Dwek MV, Ross HA, Leathem AJ: Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer. Proteomics 2001,1(6):756–762.
Ono M, Hakomori S: Glycosylation defining cancer cell motility and invasiveness. Glycoconj J 2004,20(1):71–78.
Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007, 6: 25.
Macher BA, Yen TY: Proteins at membrane surfaces-a review of approaches. Mol Biosyst 2007,3(10):705–713.
Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ: Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006,5(10):1957–1967.
Kaji H, Yamauchi Y, Takahashi N, Isobe T: Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging. Nat Protoc 2006,1(6):3019–3027.
Plavina T, Wakshull E, Hancock WS, Hincapie M: Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J Proteome Res 2007,6(2):662–671.
Ueda K, Katagiri T, Shimada T, Irie S, Sato TA, Nakamura Y, Daigo Y: Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res 2007,6(9):3475–3483.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006,24(1):115–122.
Dai Z, Fan J, Liu Y, Zhou J, Bai D, Tan C, Guo K, Zhang Y, Zhao Y, Yang P: Identification and analysis of alpha1,6-fucosylated proteins in human normal liver tissues by a target glycoproteomic approach. Electrophoresis 2007,28(23):4382–4391.
Saint-Guirons J, Zeqiraj E, Schumacher U, Greenwell P, Dwek M: Proteome analysis of metastatic colorectal cancer cells recognized by the lectin Helix pomatia agglutinin (HPA). Proteomics 2007,7(22):4082–4089.
Brockhausen I, Schutzbach J, Kuhns W: Glycoproteins and their relationship to human disease. Acta Anat (Basel) 1998,161(1–4):36–78.
Kanninen K, Goldsteins G, Auriola S, Alafuzoff I, Koistinaho J: Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett 2004,367(2):235–240.
Lu X, Zhu H: Tube-gel digestion: a novel proteomic approach for high throughput analysis of membrane proteins. Mol Cell Proteomics 2005,4(12):1948–1958.
Haqqani AS, Kelly JF, Stanimirovic DB: Quantitative protein profiling by mass spectrometry using label-free proteomics. In Methods in Molecular Biology: Genomics Protocols. Volume 439. 2nd edition. Edited by: Starkey M, Elaswarapu R. Totowa: Humana Press; 2008:241–256.
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997,25(17):3389–3402.
Schaffer AA, Aravind L, Madden TL, Shavirin S, Spouge JL, Wolf YI, Koonin EV, Altschul SF: Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. Nucleic Acids Res 2001,29(14):2994–3005.
Palagi PM, Walther D, Quadroni M, Catherinet S, Burgess J, Zimmermann-Ivol CG, Sanchez JC, Binz PA, Hochstrasser DF, Appel RD: MSight: an image analysis software for liquid chromatography-mass spectrometry. Proteomics 2005,5(9):2381–2384.
Pardali K, Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007,1775(1):21–62.
Zhao YY, Takahashi M, Gu JG, Miyoshi E, Matsumoto A, Kitazume S, Taniguchi N: Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci 2008,99(7):1304–1310.
Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006,7(2):131–142.
Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H, Reichmann E: Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005,24(12):2032–2041.
Kleijnen MF, Shih AH, Zhou P, Kumar S, Soccio RE, Kedersha NL, Gill G, Howley PM: The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol Cell 2000,6(2):409–419.
Gu J, Taniguchi N: Regulation of integrin functions by N-glycans. Glycoconj J 2004,21(1–2):9–15.
Jin H, Varner J: Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004,90(3):561–565.
Barbour W, Saika S, Miyamoto T, Ohkawa K, Utsunomiya H, Ohnishi Y: Expression patterns of beta1-related alpha integrin subunits in murine lens during embryonic development and wound healing. Curr Eye Res 2004,29(1):1–10.
Vicovac L, Aplin JD: Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat (Basel) 1996,156(3):202–216.
King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, Cress AE: The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS ONE 2008,3(10):e3535.
Pontier SM, Muller WJ: Integrins in breast cancer dormancy. Apmis 2008,116(7–8):677–684.
Lewandrowski U, Moebius J, Walter U, Sickmann A: Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach. Mol Cell Proteomics 2006,5(2):226–233.
Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003,21(6):660–666.
Isaji T, Sato Y, Zhao Y, Miyoshi E, Wada Y, Taniguchi N, Gu J: N-glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function. J Biol Chem 2006,281(44):33258–33267.
Zhao Y, Sato Y, Isaji T, Fukuda T, Matsumoto A, Miyoshi E, Gu J, Taniguchi N: Branched N-glycans regulate the biological functions of integrins and cadherins. Febs J 2008,275(9):1939–1948.
Mercurio AM, Rabinovitz I, Shaw LM: The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001,13(5):541–545.
Dowling J, Yu QC, Fuchs E: Beta4 integrin is required for hemidesmosome formation, cell adhesion and cell survival. J Cell Biol 1996,134(2):559–572.
Neut R, Krimpenfort P, Calafat J, Niessen CM, Sonnenberg A: Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice. Nat Genet 1996,13(3):366–369.
Mercurio AM, Bachelder RE, Chung J, O'Connor KL, Rabinovitz I, Shaw LM, Tani T: Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 2001,6(3):299–309.
Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006,13(1):12–19.
Jensen M, Berthold F: Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007,258(1):9–21.
Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB: Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006,66(23):11370–11380.
Kadmon G, Kowitz A, Altevogt P, Schachner M: The neural cell adhesion molecule N-CAM enhances L1-dependent cell-cell interactions. J Cell Biol 1990,110(1):193–208.
Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PW, Berns A, et al.: NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. Embo J 2008,27(19):2603–2615.
Gallagher WM, Currid CA, Whelan LC: Fibulins and cancer: friend or foe? Trends Mol Med 2005,11(7):336–340.
Yi CH, Smith DJ, West WW, Hollingsworth MA: Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 2007,170(5):1535–1545.
Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, et al.: Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007,6(10):3962–3975.
Fischer RS, Yarmola EG, Weber KL, Speicher KD, Speicher DW, Bubb MR, Fowler VM: Tropomodulin 3 binds to actin monomers. J Biol Chem 2006,281(47):36454–36465.
Fischer RS, Fritz-Six KL, Fowler VM: Pointed-end capping by tropomodulin3 negatively regulates endothelial cell motility. J Cell Biol 2003,161(2):371–380.
Yogalingam G, Hopwood JJ: Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat 2001,18(4):264–281.
Gotte M, Yip GW: Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006,66(21):10233–10237.